These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 28179966)

  • 1. Efficacy and Safety of Vildagliptin as an Add-On Therapy in Inadequately Controlled Type 2 Diabetes Patients Treated With Basal Insulin.
    Saito D; Kanazawa A; Shigihara N; Sato F; Uchida T; Sato J; Goto H; Miyatsuka T; Ikeda F; Ogihara T; Ohmura C; Watada H
    J Clin Med Res; 2017 Mar; 9(3):193-199. PubMed ID: 28179966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
    Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL
    Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin.
    Al Omari M; Khader Y; Dauod AS; Beni Yonis OA; Khassawneh AH
    J Drug Assess; 2016; 5(1):29-33. PubMed ID: 27994943
    [No Abstract]   [Full Text] [Related]  

  • 4. Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes.
    Kozlovski P; Foley J; Shao Q; Lukashevich V; Kothny W
    World J Diabetes; 2013 Aug; 4(4):151-6. PubMed ID: 23961326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
    Göke R; Gruenberger JB; Bader G; Dworak M
    Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study.
    Otowa-Suematsu N; Sakaguchi K; Nakamura T; Hara K; Kishi M; Hashimoto N; Yokota K; Yoshino H; Kuroki Y; Nishiumi T; Sou A; Komada H; Okada Y; Hirota Y; Tamori Y; Ogawa W
    Diabetes Ther; 2018 Oct; 9(5):2067-2079. PubMed ID: 30206903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Effectiveness and Safety of Vildagliptin Add-On to Metformin Versus Other Oral Dual Antidiabetes Agents in Patients with Type 2 Diabetes: The China Prospective Diabetes Study.
    Zang L; Han Y; Chen L; Hu D; Jin H; Yang N; Shi X; Liang L; Liu M; Fan H; Li Q; Mu Y
    Diabetes Ther; 2019 Aug; 10(4):1391-1405. PubMed ID: 31222594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide.
    Kudo-Fujimaki K; Hirose T; Yoshihara T; Sato F; Someya Y; Ohmura C; Kanazawa A; Fujitani Y; Watada H
    J Diabetes Investig; 2014 Jul; 5(4):400-9. PubMed ID: 25411599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of vildagliptin as add-on treatment in patients with type 2 diabetes mellitus: insights from long-term clinical studies in Japan.
    Odawara M; Sagara R
    J Diabetes Metab Disord; 2015; 15():21. PubMed ID: 27382546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Vildagliptin Add-on Insulin Therapy on Nocturnal Glycemic Variations in Uncontrolled Type 2 Diabetes.
    Li FF; Shen Y; Sun R; Zhang DF; Jin X; Zhai XF; Chen MY; Su XF; Wu JD; Ye L; Ma JH
    Diabetes Ther; 2017 Oct; 8(5):1111-1122. PubMed ID: 28921310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study.
    Forst T; Koch C; Dworak M
    Curr Med Res Opin; 2015 Jun; 31(6):1079-84. PubMed ID: 25867771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a single-pill combination of vildagliptin and metformin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial.
    Odawara M; Yoshiki M; Sano M; Hamada I; Lukashevich V; Kothny W
    Diabetes Ther; 2015 Mar; 6(1):17-27. PubMed ID: 25691359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes.
    Shigematsu E; Yamakawa T; Oba MS; Suzuki J; Nagakura J; Kadonosono K; Terauchi Y
    J Clin Med Res; 2017 Jul; 9(7):567-572. PubMed ID: 28611856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data.
    Kamenov Z
    Diabetes Ther; 2014 Dec; 5(2):483-98. PubMed ID: 25245616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and tolerability of second-line therapy with vildagliptin versus other oral agents in type 2 diabetes (EDGE): post-hoc subanalysis of the Belgian data.
    Hoste J; Daci E; Mathieu C
    Acta Clin Belg; 2014 Jun; 69(3):171-6. PubMed ID: 24820924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study.
    El Ebrashy I; El Kafrawy N; Raouf R; Yousry D
    Diabetes Res Clin Pract; 2020 Apr; 162():108042. PubMed ID: 32006641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient preference and tolerability of a DPP-4 inhibitor versus a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study.
    Lüdemann J; Dütting ED; Dworak M
    Ther Adv Endocrinol Metab; 2015 Aug; 6(4):141-8. PubMed ID: 26301063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
    Kim JH; Kim SS; Baek HS; Lee IK; Chung DJ; Sohn HS; Bae HY; Kim MK; Park JH; Choi YS; Kim YI; Hahm JR; Lee CW; Jo SR; Park MK; Lee KJ; Kim IJ
    Diabetes Metab J; 2016 Jun; 40(3):230-9. PubMed ID: 27098505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
    Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.
    Bosi E; Camisasca RP; Collober C; Rochotte E; Garber AJ
    Diabetes Care; 2007 Apr; 30(4):890-5. PubMed ID: 17277036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.